Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
No biomarker
Cancer:
Mantle Cell Lymphoma
Regimen:
R-GemOx
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
NCCN
Published date:
01/20/2021
Excerpt:
Mantle Cell Lymphoma: SECOND-LINE AND SUBSEQUENT THERAPY…Useful under Certain Circumstances…GemOx (gemcitabine + oxaliplatin) + rituximab
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.